Concepedia

Mark Lynch

ML

Statistics

Publications

67

Citations

16.7K

H-Index

35

Active since

1980

Affiliations

Bristol-Myers Squibb (United States)(Current)

National Cancer Center Hospital East

Centre Antoine Lacassagne

Centre Léon Bérard

The University of Texas MD Anderson Cancer Center

Mark Lynch is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and life sciences.

Publications per year

1980–2023

67

Publications

67

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text

Medicine, Oncology, Metastasis +5

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Medicine, Oncology, Pharmacology +17

Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5

Li Liu, Yichen Cao, Charles Chen et al. · Cancer Research · 2006 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

Scott M. Wilhelm, Jacques Dumas, Lila Adnane et al. · International Journal of Cancer · 2010 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · Oral Oncology · 2018 · 800 citations · Full text

Medicine, Oncology, Metastasis +14

1–5 of 67